Biotech Startups

Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk. The company uses a platform approach to tune drug candidates across a spectrum from inhibitors to full agonists.

3 investors

Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy. The company's lead compound, EPM-01, is in Phase 1 clinical development for Becker muscular dystrophy.

3 investors

Epistemic AI combines AI agents with a team of scientists, engineers, and business leaders to produce evidence-based analysis for biopharma and life-science decisions. Its scientists shape and review the AI-driven analysis over connected evidence to support consequential industry decisions.

3 investors

Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform. The company serves patients with difficult-to-treat cancers across oncology.

3 investors

Espervita Therapeutics develops metabolic reprogramming therapies targeting liver and kidney disease, with a lead program in acetyl-CoA metabolic enzyme inhibitors. The company focuses on treating progressive metabolic liver diseases and related conditions.

3 investors

Esphera designs transgenes that enable budding exosomes to carry multimeric proteins for therapeutic applications, with initial focus on modifying tumor-derived exosomes to create immunostimulatory cancer vaccines.

3 investors

Euclises Pharmaceuticals develops oral, small-molecule drugs targeting COX-2 to disrupt the tumor microenvironment and enhance cancer cell death, particularly when combined with immune checkpoint inhibitors or EGFR inhibitors. The company is advancing these molecules through clinical trials to improve immuno-oncology therapies.

3 investors

Euler Biologics develops antibody-based therapies aimed at preserving and enhancing physical function in older adults to support healthy aging and functional independence. The company operates in the biotech and longevity space.

3 investors

EuMentis Therapeutics develops therapies for neuropsychiatric disorders, targeting selective CNS circuits in the brain. Its lead product, EM-221, is a PDE10A inhibitor in development for schizophrenia and Parkinson's levodopa-induced dyskinesia, with a pipeline addressing conditions such as Alzheimer's-related agitation, treatment-resistant depression, bipolar disorder, and Tourette's.

3 investors

EV Biotech designs and optimizes precision fermentation strains and processes for clients seeking sustainable production methods. The company reprograms microorganisms to enable industrial-scale fermentation as an alternative to resource-intensive manufacturing.

3 investors

Eveliqure develops a live attenuated vaccine platform for oral administration targeting Shigella and ETEC pathogens that cause diarrheal disease in travelers and populations in low- and middle-income countries. The company's lead product, ShigETEC, provides broad serotype-independent protection against multiple pathogens through targeted genetic mutations.

3 investors

Everest is an AI platform that automates regulatory, clinical, and commercial document workflows for pharmaceutical, medtech, and contract research organizations (CROs), generating submission-ready documents and associated statistical analyses from source data.

3 investors

EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.

3 investors

Evodia is a Danish aroma company that uses precision fermentation with proprietary yeast strains to produce monoterpenes, the natural molecules behind flavor and aroma, as a sustainable alternative to plant-derived ingredients. Its Yops product provides customizable aroma blends for brewers, positioned as an alternative to hops in non-alcoholic and alcohol-free beer.

3 investors

EvolveImmune develops immunotherapy treatments for cancer patients. The company focuses on discovering and developing novel biotherapeutics in immuno-oncology and related immune-mediated diseases.

3 investors

EVOQ Therapeutics develops immunotherapies targeting autoimmune diseases by using proprietary NanoDisc technology to restore immune tolerance. The company focuses on treating conditions like Type 1 Diabetes, Multiple Sclerosis, and Lupus through novel therapeutic approaches.

3 investors

Exero Medical develops the xBar system, which uses electrode sensors embedded in a standard surgical drain to non-invasively monitor post-operative tissue healing and detect anastomotic leaks after gastrointestinal surgery. The system provides healthcare providers with post-operative data to enable earlier detection of complications; it is currently limited to investigational use in the US.

3 investors

ExeVir develops multi-specific VHH antibody therapies to treat infectious diseases, immunological conditions, and oncology, with a focus on immunocompromised populations. The company operates as a clinical-stage biotech firm leveraging a modular antibody platform to accelerate drug development.

3 investors

Developing CRISPR/Cas9 gene editing for neuromuscular diseases; acquired by Vertex in June 2019 for up to $1B.

3 investors

Experiment runs a crowdfunding platform where citizens pledge money to fund scientific research projects, giving researchers an alternative to traditional grant writing. Scientists use it to raise funding and share results with backers through lab notes and peer-reviewed publications.

3 investors

Epoch Biodesign is a synthetic biology company that engineers enzymes to break down plastic waste into virgin-grade feedstocks at low energy and ambient conditions. The company serves fashion, automotive, and industrial companies seeking to meet circularity targets through scalable plastic recycling solutions.

3 investors

Exthymic is a company working on cell therapy manufacturing, aiming to make cancer cell therapies more accessible to patients who currently cannot obtain them. The founders describe backgrounds building manufacturing platforms and scaling production within the cell therapy industry.

3 investors

Eywa is a team of scientists and innovators focused on advancing mental health through research and partnerships.

3 investors

Faeger generates and sells agriculture-derived carbon credits, working with farmers, local governments, and agricultural cooperatives (JA) to implement decarbonization farming methods and produce traceable credits. It sells these credits to companies seeking to support regional agriculture and their own decarbonization, and also conducts R&D on crop yield improvement and climate adaptation, with a focus on Japan.

3 investors